We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic significance of Ki67 in Chinese women diagnosed with ER<sup>+</sup>/HER2<sup>-</sup> breast cancers by the 2015 St. Gallen consensus classification.
- Authors
Yue Hu; Ran Gu; Jinghua Zhao; Yaping Yang; Fengtao Liu; Liang Jin; Kai Chen; Haixia Jia; Hongli Wang; Qiang Liu; Fengxi Su; Weijuan Jia; Hu, Yue; Gu, Ran; Zhao, Jinghua; Yang, Yaping; Liu, Fengtao; Jin, Liang; Chen, Kai; Jia, Haixia
- Abstract
<bold>Background: </bold>This study evaluated the distribution pattern of the Ki67-labeling index (LI) among patients at a Chinese breast cancer center, and analyzed its prognostic significance in the 2015 St Gallen consensus breast cancer classification, estrogen receptor-positive and human epidermal growth factor receptor 2-negative(ER+/HER2-)subtype.<bold>Methods: </bold>We classified 939 women with ER+/HER2- breast cancer into three groups by Ki67-LI levels, and followed their clinicopathologic characteristics and prognoses.<bold>Results: </bold>In the 939 eligible subjects, 342 had Ki67-LI ≤10% (Ki67Low), 281 had Ki67-LI between 10 and 30% (Ki67Medium), and 316 had Ki67-LI ≥30% (Ki67High). Although the Ki67High group had less favorable clinicopathologic factors, the Ki67Medium group's factors varied considerably. Kaplan-Meier estimates showed that disease-free survival(DFS) for the Ki67Medium group was significantly shorter than the Ki67Low group but longer than the Ki67High group. Ki67-LI had independent prognostic significance in multivariate analysis. Other diagnostic factors, including tumor size >2 cm, positive lymph nodes, and grade III disease, were significantly associated with poorer disease-free survival only in the Ki67Medium group.<bold>Conclusions: </bold>For patients with ER+/HER2- breast cancer, we confirmed three distinct risk patterns by Ki67-LI levels according to the 2015 St Gallen consensus. For patients with clearly low or high Ki67-LI, straightforward clinical decisions could be offered, but for patients with intermediate Ki67-LI, other factors might provide valuable information.
- Subjects
BREAST cancer diagnosis; BREAST cancer prognosis; CANCER treatment; CANCER patient medical care; TREATMENT of diseases in women; ASIANS; BREAST tumors; CELL receptors; GENES; PROGNOSIS; PROTEINS; TUMOR markers; KAPLAN-Meier estimator
- Publication
BMC Cancer, 2017, Vol 17, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-016-3021-7